2025 年 1 月 18 日，由北京市希思科临床肿瘤学研究基金会、杭州东方临床肿瘤研究中心共同主办的「2024 胃肠肿瘤年终大盘点」盛大召开。会议中揭榜 2024 胃肠领域十大临床热词，其中，肿瘤经典靶点人表皮生长因子受体 2（HER2）和抗 ...

Taiwan needs to revamp research into stomach cancer and increase National Health Insurance (NHI) coverage for targeted ...

Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Factors and timing of decreased adherence to S-1 in postoperative docetaxel + S-1 therapy for gastric cancer. Investigation of synergistic effects in trials of combination therapies with ...

Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.

HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

in combination with other cancer therapies, has shown a significant tumor response in patients with HER2-positive advanced gastric cancer. The trial results were presented today at the 2025 ASCO ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients ...